Navigation Links
Advanced Viral Announces Phase IIb Wound Healing Trial for AVR123
Date:10/28/2008

Receives $249,500 in Additional Financing

YONKERS, N.Y., Oct. 28 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), announced today that it has commenced a Phase IIb efficacy study for AVR123 in wound healing.

The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen Germany, led by Eckhart Kampgen, M.D., Associate Professor for Strategies of Cellular Immunotherapy at the Department of Dermatology. Dr. Kampgen is leading the Immunomonitoring, RNA and Melanoma Division at the hospital. He has over 80 peer-reviewed publications and has participated as Principal Investigator or Sub-Investigator in more than 20 Phase I, II and III clinical studies since 1995.

The primary objective of this study is to evaluate the effect of AVR123, applied topically, on the rate and quality of healing of wounds. According to the protocol, patients enrolled in the study will include individuals with a variety of wounds and dermatologic conditions.

AVR123 is a topical formulation of ARV118 which is currently being investigated for the systemic treatment of cancer related clinical cachexia. This compound has well-documented anti-inflammatory and wound healing activities. Results of a Phase I, open label, dose-escalating study indicated that topical AVR123 is well-tolerated, showing no dose-limiting toxicities. Initial observations of accelerated wound healing in a pig study at the University of Miami suggest that AVR123 may represent an important advance in the management of wounds.

Stephen Elliston, President and Chief Executive Officer of Advanced Viral, stated, "This trial has been designed to provide further evidence to substantiate encouraging preliminary results seen in the initial phase of the study, which was not completed due to the death of the study's Principal Investigator. We are highly fortunate to have Dr. Kampgen, a prestigious leader in the dermatological field
'/>"/>

SOURCE Advanced Viral Research Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... DNA Genotek, a leading provider of products... that Tepnel Pharmaceutical Services will offer Or...ts nucleic acid extraction and genotyping service....ember 1, 2009 -- DNA Genotek , a leading provider...ay announced that Tepnel Pharmaceutical Services ...
(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of the ...e; Technologies, a business development and intell...emerging nanotechnology space. The company also p...s a nanotechnology incubator. , ...ichael R. Drapp , a 34-year veteran of the high-te...
(Date:11/30/2009)...RK, Nov. 30 The Michael... today announced $1.5 million in total awards to s...isease-modifying therapies for Parkinson,s disease...hes to Drug Discovery for Parkinson,s Disease pro...on, plc (NYSE: ELN ), a neuroscience-based biote...
(Date:11/30/2009)...CHANGCHUN, China and LOS ANGELES, Nov. 30 /PRNewsw...ls, Inc. (OTC Bulletin Board: CYXN; ,China Yongxin...ufacturer, distributor and,retailer of pharmaceuti...,completed preparation for distribution of medicin...ese government recently formalized the nation,s Es...
Breaking Biology Technology:Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3
...laims Designed with Input from,Entire Food Chain, ...ck,cloning companies announced today a tracking pr...will allow food companies to identify cloned anima... The program was developed through extensive coop...itical participants in the food chain.,Representat...
...cal,Inc. (Nasdaq: BFRM ) today announced that Ste... company overview at the upcoming 26th Annual,JPMo... 7-10, 2008. BioForm,Medical,s presentation will t.... PST (11:30 am EST) at the Westin St. Francis Hot... of the webcast of BioForm Medical,s,presentation ...
.... (OTC,Bulletin Board: HTWO) announced today that ...ant Energy Trading LLC, a subsidiary of Mirant Cor...ofuel technology in utility,scale power generation...to supply its biofuel for a gas,turbine test progr...s,Morgantown Generating Station, which consumed ap...
Other Biology Technology:Top U.S. Cloning Companies Announce New System to Track Cloned Livestock 2BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008 2H2Diesel Holdings Announces Test Burn Agreement With Mirant Corp. 2H2Diesel Holdings Announces Test Burn Agreement With Mirant Corp. 3
(Date:12/1/2009)..., Antennas aren,t just for listening to the radio ...es to GPS devices. Research from North Carolina St...enna design creating shape-shifting antennas that...ging from public safety to military deployment. ,...tals, but there are limitations to how far they ca...
(Date:11/30/2009)..., CLEMSON Clemson University researchers Ron Falt...ronmental Protection Agency grant to study the saf...ns located deep below the earth,s surface. , Wit...ls believed to be the leading cause of global warm...t promising alternatives for reducing emissions us...
(Date:11/30/2009)...HOUSTON (Nov. 30, 2009) Scientists and engineers ...ine and energy will come together Dec. 7 with lea...ng oil and pumping blood. , Much like moving oil...ough the body. Both systems need clean, well-func...s or corrosion, to function efficiently. Both indu...
Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 1San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 2San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 3San Francisco Bay Area Affiliate of the Susan G Komen for the Cure Funds Over 241 2 Million This Year to Community Outreach Programs 52668 4Cyberonics Provides Update on Depression Post Approval Study 4778 1Cyberonics Provides Update on Depression Post Approval Study 4778 2Cyberonics Provides Update on Depression Post Approval Study 4778 3NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 1NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 2NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 3NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 4
...ase Control and Prevention (CDC) shows a decrease ...ed by both methicillin-resistant and methicillin-s...,Methicillin-Resistant Staphylococcus aureus Cen...Intensive Care Units, 1997, reported data from bot...NNIS) and its successor, the National Healthcare S...
... . , , In comparison to many other living creatu...ite their complexity, are quite manageable. Scient...n Martinsried have now ascertained that these inse...s by means of sophisticated network interactions. ...ive motion information in their input region from ...
...ipps Institution of Oceanography at UC San Diego h...marine ecosystems. Scripps Oceanography graduate s...val photographs spanning more than five decades to...led "trophy fish" caught around coral reefs surrou...nline in January and printed in an upcoming issue ...
Other Biology News:Press statement on new CDC MRSA study from SHEA president 2Cells with double vision 2Cells with double vision 3Cells with double vision 4Historical photographs expose decline in Florida's reef fish, new Scripps study finds 2Historical photographs expose decline in Florida's reef fish, new Scripps study finds 3
MMLV RT from Invitrogen
DNA Polymerase I, E. coli from EPICENTRE Biotechnologies
DNase I, RNase-free; special quality for molecular biology from Roche Applied Science
...ne of the human Topoisomerase II gene. Descrip...e of nucleic acids by passing an intact DNA helix ...te DNA helix (1,2) . As a result of its double-str...negatively or positively supercoiled DNA, as well ...
Biology Products: